Taken together, these data suggested that ψ-Bufarenogin could be a promising drug candidate in HCC therapy particularly in the personalized treatment of HCCs in which EGFR/c-MET-driven signaling is indispensable for cancer progression. Here, MET is linked to hepatocellular carcinoma.